Prospects for a new, safer and more effective TB vaccine

Paediatric Respiratory Reviews

Volumn 12, Issue 1, 2011, Pages 46-51

  Hawkridge, Tony ^a   Mahomed, Hassan ^a,b  

^a Aeras Global TB Vaccine Foundation South Africa   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

BCG; Heterologous prime boost; Tuberculosis; Vaccine

Indexed keywords

ADAG85A; AERAS 402; AERAS 485; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; INACTIVATED VACCINE; LIVE VACCINE; M72; MVA85A; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM ANTIGEN 85A; MYCOBACTERIUM ANTIGEN 85B; MYCOBACTERIUM ANTIGEN RV0125; MYCOBACTERIUM ANTIGEN RV1196; RECOMBINANT PROTEIN; RUTI; UNCLASSIFIED DRUG; VIRUS VECTOR; VPM 1002;

BCG VACCINATION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOLOGY; LATENT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; SYSTEMIC DISEASE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 78650240549     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.09.013     Document Type: Review

References (37)

1. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. Bmj 2008, 337:a2052.
2. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367(9517):1173-1180.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 1994, 271(9):698-702.
4. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346(8986):1339-1345.
5. Hesseling A.C., Caldwell J., Cotton M.F., Eley B.S., Jaspan H.B., Jennings K., et al. BCG vaccination in South African HIV-exposed infants--risks and benefits. S Afr Med J 2009, 99(2):88-91.
6. Fruth U., Young D. Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development. Int J Tuberc Lung Dis 2004, 8(1):151-155.
7. Haile M., Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005, 18(3):211-215.
8. Skeiky Y.A., Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006, 4(6):469-476.
9. McShane H., Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005, 7(5-6):962-967.
10. Tuberculosis Vaccine Candidates - 2009. In: Stop TB Partnership Working Group on New TB Vaccines; 2009.
11. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198(10):1491-1501.
12. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115(9):2472-2479.
13. Eisele B. (Vakzine Projekt Management), S P, Kaufmann Max Planck Institute. Personal Communication 2010.
14. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009, 179(8):724-733.
15. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2007, 2(10):e1052.
16. Brookes R.H., Hill P.C., Owiafe P.K., Ibanga H.B., Jeffries D.J., Donkor S.A., et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008, 3(8):e2921.
17. Hawkridge T., Scriba T.J., Gelderbloem S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008, 198(4):544-552.
18. McShane H. Personal Communication. In; 2010.
19. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, et al. The Novel TB Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4 and CD8 T Cells in Adults. Am J Respir Crit Care Med.
20. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18(2):283-291.
21. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74(8):4634-4643.
22. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(10):6357-6365.
23. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006, 177(9):6353-6360.
24. Olsen A.W., Williams A., Okkels L.M., Hatch G., Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72(10):6148-6150.
25. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001, 69(5):2773-2778.
26. Reed S.G., Coler R.N., Dalemans W., Tan E.V., DeLa Cruz E.C., Basaraba R.J., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 2009, 106(7):2301-2306.
27. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009, 5(7):475-482.
28. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174(10):6332-6339.
29. Hervas-Stubbs S., Majlessi L., Simsova M., Morova J., Rojas M.J., Nouze C., et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006, 74(6):3396-3407.
30. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine;28(4):1084-93.
31. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006, 86(3-4):273-289.
32. Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine;28(4):1106-16.
33. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. Aids;24(5):675-85.
34. Nicol M.P., Zar H.J. New specimens and laboratory diagnostics for childhood pulmonary tuberculosis: progress and prospects. Paediatr Respir Rev 2011, 12:16-21.
35. Behr M.A. BCG--different strains, different vaccines?. Lancet Infect Dis 2002, 2(2):86-92.
36. Grange J.M., Gibson J.A. Strain to strain variation in the immunogenicity of BCG. Dev Biol Stand 1986, 58(Pt A):37-41.
37. Mansoor N., Scriba T.J., de Kock M., et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009, 199(7):982-990.